Subscribe To
BBIO / BridgeBio Pharma Surges on Positive Heart Drug News
BBIO News
By The Motley Fool
October 24, 2023
Why BridgeBio Pharma Was a Healthy Stock Today
A well-respected financial services company initiated coverage on the biotech. It flagged it with its equivalent of a buy recommendation. more_horizontal
By Seeking Alpha
September 25, 2023
BridgeBio: Bets Acoramidis As The Pfizer Spoiler
BridgeBio Pharma's Q2 2023 YoY revenue plummeted, but PIPE financing extends cash runway to 15 months, alleviating short-term liquidity concerns. Acor more_horizontal
By GuruFocus
September 1, 2023
Andreas Halvorsen's Firm Ups Inhibrx Stake
Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stak more_horizontal
By GlobeNewsWire
August 24, 2023
BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023
PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage more_horizontal
By The Motley Fool
August 9, 2023
Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?
This young biotech might soon commercialize a new medicine. Analysts see BridgeBio's shares headed upward. more_horizontal
By The Motley Fool
July 21, 2023
Why Shares of BridgeBio Pharma Skyrocketed This Week
BridgeBio Pharma focuses on oncology and genetic diseases. The company said that acoramidis fared well in treating a heart muscle disease. more_horizontal
By GuruFocus
July 18, 2023
BridgeBio Pharma Surges on Positive Heart Drug News
BridgeBio Pharma ( BBIO , Financial) is a clinical-stage biopharmaceutical company that focuses on developing transformative medicines for patients wi more_horizontal
By Zacks Investment Research
July 18, 2023
BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate more_horizontal